DOCSLIB.ORG

Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality ACKNOWLEDGMENTS This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) by RTI International (a trade name of Research Triangle Institute, Research Triangle Park, NC) under contract number HHSP23320095651WC, with SAMHSA, U.S. Department of Health and Human Services (HHS). Rong Cai served as the Government Project Officer. PUBLIC DOMAIN NOTICE All material appearing in this publication is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, HHS. RECOMMENDED CITATION Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 13-4760, DAWN Series D-39. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013. ELECTRONIC ACCESS This publication may be downloaded from http://store.samhsa.gov. Or please call SAMHSA at 1-877-SAMHSA-7 (1-877-726-4727) (English and Español). ORIGINATING OFFICE Center for Behavioral Health Statistics and Quality Substance Abuse and Mental Health Services Administration 1 Choke Cherry Road, Rockville, MD 20857 May 2013 2 DAWN, 2011: NATIONAL ED ESTIMATES CONTENTS Page Highlights 7 All Drug-Related ED Visits ......................................................................................................... 7 Overall Drug Misuse or Abuse ................................................................................................... 8 Illicit Drugs .................................................................................................................................. 9 Nonmedical Use of Pharmaceuticals ......................................................................................... 9 Drugs and Alcohol Taken Together ........................................................................................... 9 Underage Drinking ................................................................................................................... 10 Drug-Related Suicide Attempts ................................................................................................ 10 Seeking Detox Services ........................................................................................................... 10 Adverse Reactions to Pharmaceuticals ................................................................................... 10 Accidental Ingestion of Drugs .................................................................................................. 10 1. Introduction 13 1.1 Major Features of DAWN ............................................................................................... 15 1.1.1 What Is a DAWN Case? .................................................................................... 15 1.1.2 What Drugs Are Included in DAWN? ................................................................ 15 1.1.3 What Is Covered in This Publication? ............................................................... 15 1.2 Hospital Participation in 2011 ......................................................................................... 16 1.3 Estimates of ED Visits .................................................................................................... 16 1.4 Rates of ED Visits per 100,000 Population .................................................................... 16 1.5 Sampling Error ............................................................................................................... 17 1.6 Suppression.................................................................................................................... 17 1.7 Comparisons Across Years ............................................................................................ 18 1.8 Limitations of the Data .................................................................................................... 18 2. Overall Drug Misuse or Abuse 21 2.1 ED Visits Involving Overall Drug Misuse or Abuse, 2011 .............................................. 21 2.2 Trends in ED Visits Involving Drug Misuse or Abuse, 2004–2011................................. 22 3. Illicit Drugs 25 3.1 ED Visits Involving Illicit Drugs, 2011 ............................................................................. 25 3.2 Trends in ED Visits Involving Illicit Drugs, 2004–2011 ................................................... 33 4. Alcohol 37 4.1 ED Visits Involving Drugs and Alcohol Taken Together, 2011 ...................................... 37 DAWN, 2011: NATIONAL ED ESTIMATES 3 4.2 Underage Drinking ......................................................................................................... 43 4.3 Trends in ED Visits Involving Alcohol, 2004–2011......................................................... 45 5. Nonmedical Use of Pharmaceuticals 47 5.1 ED Visits Involving Nonmedical Use of Pharmaceuticals, 2011 .................................... 47 5.2 Trends in ED Visits Involving Nonmedical Use of Pharmaceuticals, 2004–2011 .......... 53 6. Drug-Related Suicide Attempts 59 6.1 ED Visits Involving Drug-Related Suicide Attempts, 2011 ............................................. 59 6.2 Trends in ED Visits Involving Drug-Related Suicide Attempts, 2004–2011 ................... 65 7. Seeking Detox Services 69 7.1 ED Visits Involving Seeking Detox Services, 2011 ........................................................ 69 7.2 Trends in ED Visits Involving Seeking Detox Services, 2004–2011 .............................. 73 8. Adverse Reactions To Pharmaceuticals 75 8.1 ED Visits Involving Adverse Reactions to Pharmaceuticals, 2011 ................................ 75 8.2 Trends in ED Visits Involving Adverse Reaction to Pharmaceuticals, 2005– 2011 ................................................................................................................................ 80 9. Accidental Ingestion of Drugs 85 9.1 ED Visits Involving Accidental Ingestion of Drugs, 2011 ............................................... 85 9.2 Trends in ED Visits Involving Accidental Ingestion of Drugs by Patients Aged 5 and Under, 2004–2011 ................................................................................................... 91 4 DAWN, 2011: NATIONAL ED ESTIMATES List of Tables Table 1. DAWN analytic groups .................................................................................................. 13 Table 2. ED visits involving drug misuse or abuse, by drug combinations, 2011 ...................... 21 Table 3. Trends in ED visits involving drug misuse or abuse, by drug combinations, 2004–2011 .................................................................................................................... 23 Table 4. ED visits involving illicit drugs, 2011 ............................................................................. 26 Table 5. Rates of ED visits per 100,000 population involving illicit drugs, 2011 ........................ 28 Table 6. ED visits involving illicit drugs, by patient demographics, 2011 ................................... 30 Table 7. Rates of ED visits per 100,000 population involving illicit drugs, by patient demographics, 2011 ..................................................................................................... 31 Table 8. ED visits and rates involving illicit drugs, by patient disposition, 2011 ......................... 33 Table 9. Trends in ED visits involving illicit drugs, by selected drugs, 2004–2011 .................... 34 Table 10. ED visits involving alcohol, 2011 .................................................................................. 37 Table 11. ED visits involving drugs and alcohol taken together, 2011 ......................................... 38 Table 12. ED visits involving alcohol, by drug, 2011 .................................................................... 40 Table 13. ED visits involving drugs and alcohol taken together, by patient demographics, 2011 .............................................................................................................................. 41 Table 14. ED visits involving drugs and alcohol taken together, by patient disposition, 2011 .............................................................................................................................. 42 Table 15. ED visits involving underage drinking, 2011 ................................................................. 43 Table 16. ED visits involving alcohol, by patients aged 12 to 17 and 18 to 20, 2011 .................. 44 Table 17. Trends in ED visits involving alcohol, 2004–2011 ........................................................ 46 Table 18. ED visits involving nonmedical use of pharmaceuticals, by selected drugs, 2011....... 49 Table 19. ED visits and rates involving nonmedical use of pharmaceuticals, by patient demographics, 2011 ..................................................................................................... 51 Table 20. ED visits and rates involving nonmedical use of pharmaceuticals, by patient disposition, 2011 ..........................................................................................................
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Hygroscopicity of Pharmaceutical Crystals
    HYGROSCOPICITY OF PHARMACEUTICAL CRYSTALS A DISSERTATION SUBMITTED TO THE FACULTY OF GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY DABING CHEN IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY RAJ SURYANARAYANAN (ADVISER) JANUARY, 2009 © Dabing Chen, January / 2009 ACKNOWLEDGEMENTS I am very grateful to my thesis advisor, Prof. Raj Suryanarayanan, for his constant guidance, support, and encouragement throughout my research. Without his help, the completion of this thesis would be impossible. His friendship and advices are precious to my professional and personal growth and will help me overcome many difficulties in my future career. I would like to take the opportunity to thank Prof. David J.W. Grant, who was my advisor during the first three years in graduate school and led me into the research area of physical pharmacy. It was my great honor to have worked for him, and he will always live as a role model in my life. Many thanks to Dr. Zheng Jane Li at Boehringer Ingelheim Pharmaceuticals (BI) for her invaluable advice as an industrial mentor and also for agreeing to serve on my committee. I sincerely appreciate her helpful discussions, revision of the manuscripts, and supervision of my research. I also want to thank her for providing me the internship opportunity at BI. I thank Dr. Timothy S. Wiedmann and Dr. Theodore P. Labuza for serving on my committee and for critically reviewing my thesis. I also want to thank Dr. Timothy S. Wiedmann for allowing me the use of the HPLC instruments in his lab and also for his advice as the Director of Graduate Studies.
    [Show full text]
  • F 009 035 Benzocaine 20%, Lidocaine Hydrochoride 7
    MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 [email protected] 1/4/2021; Page 1 Suggested Benzocaine 20%, Lidocaine Hydrochloride 7%, Tetracaine Hydrochloride 7% FIN F 009 035 Formula Topical Gel (Suspension, 30 g) SUGGESTED FORMULATION Lot Expiry Ingredient Listing Qty. Unit NDC # Supplier Number Date Benzocaine, USP 6.000 g Lidocaine Hydrochloride, USP TBD Tetracaine Hydrochloride, USP 2.100 g Polysorbate 80, NF 0.5 mL Ethoxy Diglycol, NF 0.5 mL Medisca VersaPro™ Anhydrous Base 1.50 g Medisca VersaPro™ Anhydrous Base TBD MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 [email protected] 1/4/2021; Page 2 Suggested Benzocaine 20%, Lidocaine Hydrochloride 7%, Tetracaine Hydrochloride 7% FIN F 009 035 Formula Topical Gel (Suspension, 30 g) SPECIAL PREPARATORY CONSIDERATIONS Ingredient-Specific Information Benzocaine, Tetracaine Hydrochloride, Polysorbate Light Sensitive (protect from light whenever possible): 80 Tetracaine Hydrochloride, Polysorbate 80, Ethoxy Hygroscopic (protect from moisture whenever possible): Diglycol Oxygen Sensitive (protect from air whenever possible): Polysorbate 80 Narrow Therapeutic Index Lidocaine Hydrochloride Suggested Preparatory Guidelines ■ Non-Sterile Preparation □ Sterile Preparation Processing Error / To account for processing error considerations during preparation, it is suggested to Testing Considerations: measure an additional 12 to 15% of the required quantities of ingredients. Special Instruction: This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings.
    [Show full text]
  • What Are Anticoagulants and Antiplatelet Agents?
    ANSWERS Treatments + Tests by heart What are Blood clots are made up of red blood cells, platelets, fibrin, and white blood Anticoagulants cells (shown below). Anticoagulants and antiplatelets keep these parts from and Antiplatelet sticking together and forming a clot. Agents? Anticoagulants and antiplatelets are medicines that reduce blood clotting in an artery, vein or the heart. Doctors prescribe these to help prevent heart attacks and strokes caused by blood clots. Blood clots can block blood flow to your heart or your brain causing a heart attack or stroke. What should I know about anticoagulants? • Discuss your diet with your health care providers. Foods rich in Vitamin K can reduce the effectiveness of Anticoagulants (sometimes known as “blood thinners”) are warfarin. Vitamin K is in leafy, green vegetables, fish, medicines that delay the clotting of blood. Examples are liver, lentils, soybeans and some vegetable oils. heparin, warfarin, dabigitran, apixaban, rivoraxaban and edoxaban. • Tell your family that you take anticoagulant medicine. Anticoagulants make it harder for blood clots to form in your • Always carry your emergency medical ID card. heart, veins and arteries. They also can keep existing clots from growing larger. It’s important to follow these tips while on anticoagulants: Could anticoagulants cause problems? • Take your medications exactly as prescribed. If you do as your doctor tells you, there probably won’t be problems. But you must tell them right away if: • If you take warfarin, have regular blood tests so your health care provider can tell how the medicine is working. • You think you’re pregnant or you’re planning to get pregnant.
    [Show full text]
  • Do You Know... Cocaine
    Do You Know... Street names: blow, C, coke, crack, flake, freebase, rock, snow Cocaine What is cocaine? Cocaine is a stimulant drug. Stimulants make people feel more alert and energetic. Cocaine can also make people feel euphoric, or “high.” Pure cocaine was first isolated from the leaves of the coca bush in 1860. Researchers soon discovered that cocaine numbs whatever tissues it touches, leading to its use as a local anesthetic. Today, we mostly use synthetic anesthetics, rather than cocaine. In the 1880s, psychiatrist Sigmund Freud wrote scientific papers that praised cocaine as a treatment for many ailments, including depression and alcohol and opioid addiction. After this, cocaine became widely and legally available in patent medicines and soft drinks. As cocaine use increased, people began to discover its dangers. In 1911, Canada passed laws restricting the importation, manufacture, sale and possession of cocaine. The use of 1/4 © 2003, 2010 CAMH | www.camh.ca cocaine declined until the 1970s, when it became known How does cocaine make you feel? for its high cost, and for the rich and glamorous people How cocaine makes you feel depends on: who used it. Cheaper “crack” cocaine became available · how much you use in the 1980s. · how often and how long you use it · how you use it (by injection, orally, etc.) Where does cocaine come from? · your mood, expectation and environment Cocaine is extracted from the leaves of the Erythroxylum · your age (coca) bush, which grows on the slopes of the Andes · whether you have certain medical or psychiatric Mountains in South America.
    [Show full text]
  • Medication Safety in Nursing Homes Change Package
    Medication Safety in Nursing Homes CHANGE PACKAGE Version 1 | June 2020 WWW.TMFNETWORKS.ORG TABLE OF CONTENTS Acronyms . 3 Introduction . 4 The Quality Improvement Process Using PDSA . 5 References . 23 Change Package Pain Management and Opioid Use 7 > Use evidence-based approaches to manage and treat acute and chronic pain . 7 > Educate residents, resident representatives, medical and clinical staff on safe use of opioids and alternative pain management strategies . 8 > Improve communication . 9 > Improve staff understanding of regulatory guidelines . .9 . Anticoagulant Medications 10 > Reduce number of ADEs Related to Anticoagulant Medications . 11 > Provide reference tools for providers . 11. > Improve communication . 12 > Provide resident education on anticoagulation therapy . .12 . > Increase staff understanding of regulatory guidelines . 13. Antipsychotic Medications 14 > Implement safe use of antipsychotic drugs in the long- and short-stay nursing home resident . 14 > Implement safe use of antipsychotic medications for those with dementia diagnosis . 15 > Improve communication . 15 > Increase staff understanding of regulatory guidelines . 16. Antimuscarinic Medications 17 > Reduce number of residents with a fall related to antimuscarinic medication . 17 > Improve communication . 18 > Increase staff understanding of regulatory guidelines . 18. Diabetes Medications 19 > Eliminate sliding-scale insulin . 20 . > Safe diabetes and medication management . 20 . > Improve communication . 21 > Reduce and prevent incidence of hypoglycemic events . 21 > Increase staff understanding of regulatory guidelines . 22. This material was developed by TMF Health Quality Institute, the Medicare Quality Innovation Network-Quality Improvement Organization, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. This content does not necessarily reflect CMS policy.
    [Show full text]
  • Commonly Used Drugs
    Commonly Used Drugs Many drugs can alter a person’s thinking and judgment, and can lead to health risks, including addiction, drugged driving, infectious disease, and adverse effects on pregnancy. Information on commonly used drugs with the potential for misuse or addiction can be found here. For information about treatment options for substance use disorders, see NIDA’s Treatment pages. For drug use trends, see our Trends and Statistics page. For the most up-to-date slang terms, please see Slang Terms and Code Words: A Reference for Law Enforcement Personnel (DEA, PDF, 1MB). The following drugs are included in this resource: ➢ Alcohol ➢ Methamphetamine ➢ Ayahuasca ➢ Over-the-Counter Medicines--Dextromethorphan ➢ Central Nervous System Depressants (DXM) ➢ Cocaine ➢ Over-the-Counter Medicines--Loperamide ➢ DMT ➢ PCP ➢ GHB ➢ Prescription Opioids ➢ Hallucinogens ➢ Prescription Stimulants ➢ Heroin ➢ Psilocybin ➢ Inhalants ➢ Rohypnol® (Flunitrazepam) ➢ Ketamine ➢ Salvia ➢ Khat ➢ Steroids (Anabolic) ➢ Kratom ➢ Synthetic Cannabinoids ➢ LSD ➢ Synthetic Cathinones ("Bath Salts") ➢ Marijuana (Cannabis) ➢ Tobacco/Nicotine ➢ MDMA (Ecstasy/Molly) ➢ Mescaline (Peyote) **Drugs are classified into five distinct categories or schedules “depending upon the drug’s acceptable medical use and the drug’s abuse or dependency potential.” More information and the most up-to-date scheduling information can be found on the Drug Enforcement Administration’s website. June 2020 Alcohol People drink to socialize, celebrate, and relax. Alcohol often has a strong effect on people—and throughout history, people have struggled to understand and manage alcohol’s power. Why does alcohol cause people to act and feel differently? How much is too much? Why do some people become addicted while others do not? The National Institute on Alcohol Abuse and Alcoholism is researching the answers to these and many other questions about alcohol.
    [Show full text]
  • Adverse Effects of Medications on Oral Health
    Adverse Effects of Medications on Oral Health Dr. James Krebs, BS Pharm, MS, PharmD Director of Experiential Education College of Pharmacy, University of New England Presented by: Rachel Foster PharmD Candidate, Class of 2014 University of New England October 2013 Objectives • Describe the pathophysiology of various medication-related oral reactions • Recognize the signs and symptoms associated with medication-related oral reactions • Identify the populations associated with various offending agents • Compare the treatment options for medication-related oral reactions Medication-related Oral Reactions • Stomatitis • Oral Candidiasis • Burning mouth • Gingival hyperplasia syndrome • Alterations in • Glossitis salivation • Erythema • Alterations in taste Multiforme • Halitosis • Oral pigmentation • Angioedema • Tooth discoloration • Black hairy tongue Medication-related Stomatitis • Clinical presentation – Aphthous-like ulcers, mucositis, fixed-drug eruption, lichen planus1,2 – Open sores in the mouth • Tongue, gum line, buccal membrane – Patient complaint of soreness or burning http://www.virtualmedicalcentre.com/diseases/oral-mucositis-om/92 0 http://www.virtualmedicalcentre.com/diseases/oral-mucositis-om/920 Medication-related Stomatitis • Offending agents1,2 Medication Indication Patient Population Aspirin •Heart health • >18 years old •Pain reliever • Cardiac patients NSAIDs (i.e. Ibuprofen, •Headache General population naproxen) •Pain reliever •Fever reducer Chemotherapy (i.e. •Breast cancer •Oncology patients methotrexate, 5FU, •Colon
    [Show full text]
  • Fenestrations Control Resting-State Block of a Voltage-Gated Sodium
    Fenestrations control resting-state block of a voltage- gated sodium channel Tamer M. Gamal El-Dina,1, Michael J. Lenaeusa,b,1, Ning Zhenga,c,2,3, and William A. Catteralla,2,3 aDepartment of Pharmacology, University of Washington, Seattle, WA 98195; bDivision of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA 98195; and cHoward Hughes Medical Institute, University of Washington, Seattle, WA 98195 Contributed by William A. Catterall, October 31, 2018 (sent for review September 4, 2018; reviewed by Ryan Hibbs, Michael C. Sanguinetti, and Joerg Striessnig) Potency of drug action is usually determined by binding to a specific Receptor Hypothesis posits that resting-state block is mediated receptor site on target proteins. In contrast to this conventional by drug entry from the lipid phase of the membrane into the drug paradigm, we show here that potency of local anesthetics (LAs) and receptor site in the pore, and rapid open-state block occurs as the antiarrhythmic drugs (AADs) that block sodium channels is con- drug enters the open pore from the cytoplasm (15). Both of these trolled by fenestrations that allow drug access to the receptor site forms of block are enhanced when the channel enters the inac- directly from the membrane phase. Voltage-gated sodium channels tivated state, which has high affinity for bound drug (15). It is initiate action potentials in nerve and cardiac muscle, where their well-established that LAs and AADs can reach their binding site hyperactivity causes pain and cardiac arrhythmia, respectively. LAs from the intracellular side if the activation gate is open, which and AADs selectively block sodium channels in rapidly firing nerve gives open-state block, and that inactivation increases the affinity and muscle cells to relieve these conditions.
    [Show full text]
  • Medication Guide for a Safe Recovery
    Medication Guide For A Safe Recovery A guide to maintaining sobriety while receiving treatment for other health problems. Revision 1.0 -April 2008 Table of Contents Introduction..................................................................................2 How to Use this Guide..................................................................3 Class A Drugs (Absolutely Avoid)................................................4 Class B Drugs................................................................................8 (With Addiction Medicine Specialist/Doctor Approval Only) Class C Drugs (Generally Safe to Take).....................................12 Alcohol-Free Products..................................................................16 Incidental Exposure Index...........................................................22 www.talbottcampus.com Introduction From the Talbott Recovery Campus Welcome to the Talbott Recovery Campus guide for a safe and sustained recovery. This document was developed through a collaborative effort between some of the best minds in addiction care today and will help you make wise decisions, ensuring that medications you may be prescribed and incidental exposure to alcohol do not threaten your hard won recovery. This guide is divided into three sections and is based on the drug classification system developed nearly 20 years ago by Dr. Paul Earley and recently expanded on by Bruce Merkin, M.D., Renee Enstrom, Nicholas Link and the staff at Glenbeigh hospital. Part one provides a way of categorizing medications
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • The Role of Corticosteroids in Primary Antiphospholipid Antibody Syndrome Presenting As Cerebral Venous Thrombosis in Young Females at Peripartum
    E. A. Ashok Kumar, P. Jijiya Bai. The role of corticosteroids in primary antiphospholipid antibody syndrome presenting as cerebral venous thrombosis in young females at peripartum. IAIM, 2016; 3(8): 97-110. Original Research Article The role of corticosteroids in primary antiphospholipid antibody syndrome presenting as cerebral venous thrombosis in young females at peripartum E. A. Ashok Kumar1*, P. Jijiya Bai2 1Professor, Department of Medicine, 2Professor, Department of Pathology, MNR Medical College and Hospital, Medak, Telangana, India *Corresponding author email: [email protected] International Archives of Integrated Medicine, Vol. 3, Issue 8, August, 2016. Copy right © 2016, IAIM, All Rights Reserved. Available online at http://iaimjournal.com/ ISSN: 2394-0026 (P) ISSN: 2394-0034 (O) Received on: 11-07-2016 Accepted on: 30-07-2016 Source of support: Nil Conflict of interest: None declared. How to cite this article: E. A. Ashok Kumar, P. Jijiya Bai. The role of corticosteroids in primary antiphospholipid antibody syndrome presenting as cerebral venous thrombosis in young females at peripartum. IAIM, 2016; 3(8): 97-110. Abstract The clinical study of cerebral venous thrombosis in antiphospholipid antibody syndrome in young females at peripartum was done to study the incidence of antiphospholipid antibodies in highly susceptible population groups most commonly at peripartum women. The presence of these antibodies points towards increased susceptibility to thrombosis and ischemic stroke apart from other manifestations in peripartum period. The age group most affected was between 20-25 years. Most of them were primipara. Many of the patients underwent Cesarean section before the presentation with the specific neurological complaint. None of the patients gave positive history for use of oral contraceptive pills.
    [Show full text]